DEF: Cocrystal Pharma Seeks Stockholder Approval for Director Elections, Auditor Ratification, and New Equity Incentive Plan

Cocrystal Pharma is holding its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, and approval of a new equity incentive plan.

Summary

• Cocrystal Pharma is convening its 2025 Annual Meeting of Stockholders on June 25, 2025, at 11:00 a.m. Eastern Time, to be held virtually via audio conference call.
• Stockholders will vote on the election of six directors for one-year terms, ratification of Weinberg & Company as the independent registered public accounting firm for the year ending December 31, 2025, and approval of the 2025 Equity Incentive Plan.
• A proposal to approve an adjournment of the Annual Meeting, if necessary, to permit further solicitation of proxies will also be voted on.
• The record date for determining stockholders entitled to notice of and to vote at the Annual Meeting is April 29, 2025.
• The company is furnishing proxy materials online, with a Notice of Internet Availability mailed to stockholders on or about May 7, 2025.
• As of the record date, there were 10,173,790 shares of common stock issued, outstanding, and entitled to vote.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting factual information about the upcoming annual meeting and proposals. The recommendation to vote FOR all proposals suggests a positive outlook from the Board.

Positives

• The company is proactively seeking stockholder approval for key governance matters.
• The 2025 Equity Incentive Plan is designed to attract, retain, and incentivize key employees.
• The company is utilizing electronic delivery of proxy materials to reduce environmental impact.
• The Board is recommending a vote FOR all proposals.

Risks

• Failure to obtain stockholder approval for the Equity Incentive Plan could hinder the company's ability to attract and retain key employees.
• The company has a history of net losses, which could impact its ability to provide competitive compensation packages.
• The company's stock price has fluctuated significantly in the past, which could impact the value of equity-based compensation.

Future Outlook

The company seeks to incentivize its key employees with long-term compensation awards, such as stock options and restricted stock, to further the growth and development of the Company.

Industry Context

The use of equity incentive plans is a common practice in the pharmaceutical industry to align the interests of employees and shareholders and to attract and retain talent in a competitive labor market.

Comparison to Industry Standards

• Cocrystal Pharma's executive compensation structure, including base salary, bonus, and equity awards, is generally consistent with that of other small-cap pharmaceutical companies.
• The proposed 2025 Equity Incentive Plan is similar to those offered by comparable companies, such as OPKO Health, Inc. and Eloxx Pharmaceuticals, Inc., in terms of the types of awards offered and the number of shares reserved for issuance.
• The company's reliance on stock options and restricted stock units as key components of executive compensation is also in line with industry standards.

Legal Proceedings

• On September 7, 2018, the SEC filed a complaint against Dr. Philip Frost, a director and principal stockholder of the Company, a trust Dr. Frost controls and OPKO Health, Inc., a stockholder of the Company, of which Dr. Frost is the Chief Executive Officer, as well as other defendants named therein.
• On January 10, 2019, the District Court entered final judgments against these defendants on their consent without admitting or denying the allegations set forth in the complaint.
• Dr. Frost was permanently enjoined from violating a certain anti-fraud provision of the Securities Act of 1933, future violations of Section 13(d) of the Exchange Act and Rule 13d-1(a) thereunder and participating in penny stock offerings subject to certain exceptions.

Related Party Transactions

• On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company.
• The Company paid a lease deposit of $4,000 on the original agreement and total rent and other expenses paid in connection with this lease were $62,000 and $63,000 for the years ended December 31, 2024 and 2023, respectively.
• On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors including Frost Gamma Investments Trust, a trust in which Phillip Frost, M.D., a director of the Company, is the trustee whereby each purchaser purchased 1,015,229 shares of common stock at a price of $1.97 per share, or two equal $2,000,000 investments.
• The second purchaser was Fred Hassan, who several weeks later was appointed a director of the Company.

Stakeholder Impact

• Approval of the Equity Incentive Plan could positively impact employees by providing them with long-term incentives.
• The election of directors will determine the leadership and strategic direction of the company, impacting shareholders.
• Ratification of the independent auditor ensures the integrity of the company's financial reporting, benefiting investors and creditors.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote their shares.
• The company will announce the results of the Annual Meeting in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Equity Incentive Plan, Weinberg & Company, Auditor, Compensation, Governance, Cocrystal Pharma